4/1/2008

Schering-Plough Corp. and Merck & Co. are stepping up efforts to promote Vytorin and Zetia after a panel of cardiologists recommended limiting the use of the cholesterol treatments. The companies reportedly plan to resume direct-to-consumer advertising and approach managed care plans and pharmacy-benefit managers.

Related Summaries